Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 4Phase 1/2 3Phase 3 2

Status

Withdrawn 3Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Leukemia, Myeloid, Acute 9Lymphoma, Mantle-Cell 8Breast Neoplasms 7Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell 5Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Recurrence 4Neuroblastoma 4Myelodysplastic Syndromes 4Mycosis Fungoides 4Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Leukemia 4Congenital Abnormalities 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Glioblastoma 3Burkitt Lymphoma 3

Interventions

Dexamethasone 338Bortezomib 188Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × Vorinostat × Clear all
NCT00773838 2021-04-01

MK-0683-095

Merck Sharp & Dohme LLC

Phase 2 Completed
143 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT01501370 2016-05-10

ZLd_Ld

University of Turin, Italy

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01492881 2012-05-11

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡